Double blind randomised control trials for new drugs form a benchmark for such tests. This approach requires two groups to be chosen differing only in whether they have a new drug or a placebo, with neither the patient nor the physician being aware who is getting which. Provided that all such studies of each new drug are published – a controversial area – there are two comparable groups, and valid statistical inferences can be drawn about whether the drug has been effective.